Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
GeoVax Labs, Inc. Market Cap
From what 5 stock analysts predict, the share price for GeoVax Labs, Inc. (GOVX) might increase by 437.88% in the next year. This is based on a 12-month average estimation for GOVX. Price targets go from $8 to $20. The majority of stock analysts believe GOVX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
GeoVax Labs, Inc. has a total of 5 Wall St Analyst ratings. There are 5 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that GeoVax Labs, Inc. will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of GOVX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Vernon Bernardino HC Wainwright & Co. | Buy | $8 | Reiterates | Nov 20, 2024 |
| Jason Kolbert D. Boral Capital | Buy | $18 | Maintains | Nov 19, 2024 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $8 | Reiterates | Nov 15, 2024 |
| Jason Kolbert D. Boral Capital | Buy | $18 | Maintains | Nov 13, 2024 |
| James Molloy Alliance Global Partners | Buy | $15 | Initiates | Nov 11, 2024 |
| Jason Kolbert EF Hutton | Buy | $18 | Maintains | Oct 2, 2024 |
| Robert LeBoyer Noble Capital Markets | Outperform | $10 | Maintains | Aug 19, 2024 |
| Jason Kolbert EF Hutton | Buy | $18 | Maintains | Aug 19, 2024 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $8 | Reiterates | Aug 12, 2024 |
| Jason Kolbert EF Hutton | Buy | $18 | Maintains | Aug 7, 2024 |
| Jason Kolbert EF Hutton | Buy | $18 | Initiates | Jul 23, 2024 |
| Jonathan Aschoff Roth MKM | Buy | $20 | Initiates | Jul 16, 2024 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $8 | Reiterates | Jul 2, 2024 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $120 | Maintains | Jun 18, 2024 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $8 | Reiterates | Nov 13, 2023 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $8 | Reiterates | Oct 9, 2023 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $8 | Reiterates | Aug 31, 2023 |
| Robert LeBoyer Noble Capital Markets | Outperform | $6 | Initiates | May 8, 2023 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $8 | Reiterates | May 8, 2023 |
| Vernon Bernardino HC Wainwright & Co. | Buy | $8 | Reiterates | Mar 24, 2023 |
When did it IPO
2020
Staff Count
17
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. David Alan Dodd
Market Cap
$25.6M
In 2023, GOVX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that GOVX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - GeoVax Labs' CEO David Dodd will present at the NobleCon20 conference from December 2-5, 2024, highlighting the company's focus on vaccines and cancer therapies.
Why It Matters - GeoVax Labs' CEO presenting at a significant investment conference highlights potential growth opportunities and increased visibility, which can impact stock performance and investor confidence.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - GeoVax Labs, Inc. (GOVX) held its Q3 2024 earnings call, providing updates on financial performance and strategic initiatives. Details on revenue, expenses, and future outlook were discussed.
Why It Matters - The Q3 2024 earnings call for GeoVax Labs provides insights into financial performance and strategic direction, influencing investor sentiment and stock valuation.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The GEO-CM04S1 BARDA/Project NextGen Phase 2b trial is progressing, with multiple COVID-19 vaccine Phase 2 trial data readouts anticipated in Q4 2024.
Why It Matters - Progress in COVID-19 vaccine trials signals potential for effective new treatments, impacting vaccine makers' stock performance and market dynamics in the healthcare sector.
Tue, 05 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - GeoVax Labs, Inc. (Nasdaq: GOVX) will report Q3 2024 financial results on November 12, 2024, after market close, followed by a conference call at 4:30 PM ET.
Why It Matters - The upcoming earnings report and conference call may influence GeoVax's stock price, providing insights into financial health and future prospects that could affect investor sentiment.
Wed, 02 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - GeoVax Labs, Inc. (GOVX) will participate in the ROTH Healthcare Opportunities Conference on October 9, 2024, with CEO David Dodd discussing therapies for solid tumors and hosting one-on-one meetings.
Why It Matters - David Dodd's participation in a major healthcare conference highlights GeoVax's focus on innovative therapies, potentially boosting investor interest and confidence in its future prospects.
Tue, 03 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - GeoVax Labs, Inc. (Nasdaq: GOVX) announced that Chairman and CEO David Dodd will present at two upcoming investor events.
Why It Matters - David Dodd's presentations can influence investor perception and confidence in GeoVax's potential, affecting stock performance and market interest in the company's pipeline.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
